NCT06905288Recruiting
Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.
Real-world Observational Study to Evaluate the Effectiveness of Secukinumab in Biologic-naive Ankylosing Spondylitis Patients in Korea
Source: ClinicalTrials.gov · Last updated 18 Aug 2026
Brief summary (registry, in English)
This is an observational study to evaluate the effectiveness and safety of secukinumab in participants with AS who have never used TNFi, JAKi, or IL-17i drugs before.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 70 (estimated)
- First submitted
- 25 Mar 2025
- Start date
- 2 Apr 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Novartis Pharmaceuticals
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT06905288
What you commit to
- Study type: Observational
- Planned participants: 70
- From 2 Apr 2025 to the primary completion date, 31 Dec 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Subjects who are in a medical or psychological condition which may prevent them from participating in the study for the study period(28±4 weeks)
Other
- Subjects who have congenital/traumatic spinal deformities
- Subjects currently enrolled in other clinical studies
- Subjects who have any contraindications to secukinumab treatment
Who the study is looking for
- Subjects diagnosed with ankylosing spondylitis (AS), as defined by the modified 1984 New York criteria
- Subjects who have symptoms of active disease at screening and baseline, as evidenced by BASDAI score of ≥ 4
- Subjects who have never used TNFi, JAKi, or IL-17i drugs before
- Patients suitable for secukinumab treatment within the scope of labeling by the Ministry of Food and Drug Safety
- Subjects who have a time of less than 5 years since AS diagnosis
- Subjects who are above the age of 18 years and below 40years old
- Subjects who give informed consent form to participate in the study
Age in the registry: 18 years to 40 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novartis Investigative Site Coordinator of this site? Confirm its status | Busan | South Korea | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Gwangju | South Korea | Recruiting |
| Novartis Investigative Site Coordinator of this site? Confirm its status | Jinju | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.